title: BRCA-deficient and triple negative breast cancers: is olaparib effective in both subtypes?
authors.forename: I
authors.initials: I
authors.lastname: Sahin
authors.forename: E
authors.initials: E
authors.lastname: Ararat
authors.forename: K
authors.initials: K
authors.lastname: Altundag
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D019398:Genes, BRCA1; D006801:Humans; D009154:Mutation; D010793:Phthalazines / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors
chemical_list: D000970:Antineoplastic Agents; D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C531550:olaparib